ReviewCartilage2019
A Review of Commercially Available Point-of-Care Devices to Concentrate Bone Marrow for the Treatment of Osteoarthritis and Focal Cartilage Lesions.
Review in Cartilage, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Bone marrow concentrate injections for the treatment of osteoarthritis: evidence from preclinical findings to the clinical application.International orthopaedics · 2021Pooled it
- Technology behind augmenting fracture healing.Bulletin of the Hospital for Joint Disease (2013) · 2025Review
- Prolonged irrigation time in endoscopic aqueous medium impairs MSC/β-TCP adhesion and osteogenic potential.Scientific reports · 2025Article
- Current Non-Surgical Curative Regenerative Therapies for Knee Osteoarthritis.Stem cell reviews and reports · 2024Review
- Mesenchymal Stromal Cells in Acute Respiratory Distress Syndrome: More Questions Than Answers.American journal of respiratory and critical care medicine · 2023Article
- Methods of Conservative Intra-Articular Treatment for Osteoarthritis of the Hip and Knee.Deutsches Arzteblatt international · 2023Review
- Erythrocyte removal from bone marrow aspirate concentrate improves efficacy as intra-articular cellular therapy in a rodent osteoarthritis model.Annals of translational medicine · 2023Article
- Patient Demographic Factors Are Not Associated With Mesenchymal Stromal Cell Concentration in Bone Marrow Aspirate Concentrate.Arthroscopy, sports medicine, and rehabilitation · 2023Article
- Challenges Facing the Translation of Embryonic Stem Cell Therapy for the Treatment of Cartilage Lesions.Stem cells translational medicine · 2022Review
- Reorientation technique has benefits in bone marrow aspiration of stem cells.Scientific reports · 2022Article
- Combined Bone Marrow Aspirate and Platelet-Rich Plasma for Cartilage Repair: Two-Year Clinical Results.Cartilage · 2021Article
- Subchondral and intra-articular injections of bone marrow concentrate are a safe and effective treatment for knee osteoarthritis: a prospective, multi-center pilot study.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2021Article
- Red blood cells and their releasates compromise bone marrow-derived human mesenchymal stem/stromal cell survival in vitro.Stem cell research & therapy · 2021Article
- Platelet-rich plasmaWorld journal of stem cells · 2021Review
- Ceramic Scaffolds in a Vacuum Suction Handle for Intraoperative Stromal Cell Enrichment.International journal of molecular sciences · 2020Article
- Cell-secreted extracellular matrix influences cellular composition sequestered from unprocessed bone marrow aspirate for osteogenic grafts.Biomaterials science · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMesenchymal stem cells (MSCs) are a promising cell-based therapy treatment option for several orthopedic indications. Because culture expansion of MSC is time and cost intensive, a bedside concentration of bone marrow (BM) aspirate is used as an alternative. Many commercial systems are available but the available literature and knowledge regarding these systems is limited. We compared different point-of-care devices that concentrate BM (BMC) by focusing on technical features and quality parameters to help surgeons make informed decisions while selecting the appropriate device.
methodsWe compared published data on the BMC devices of Arteriocyte, Arthrex, Celling Biosciences, EmCyte, Exactech, ISTO Tech, Harvest Tech/Terumo BCT, and Zimmer/BIOMET regarding technical features (centrifugation speed/time, input/output volume, kit components, type of aspiration syringes, filter usage) and quality parameters of their final BMC product (hematocrit, concentration of platelets and total nucleated cells, concentration of MSC and connective tissue progenitor cells).
resultsThe systems differ significantly in their technical features and centrifugation parameters. Only the fully automated systems use universal kits, which allow processing different volumes of BM. Only the Arthrex system allows selection of final hematocrit. There was no standardized reporting method to describe biologic potency.
conclusionsBased on the data obtained in this review, recommending a single device is not possible because the reported data could not be compared between devices. A standardized reporting method is needed for valid comparisons. Furthermore, clinical outcomes are required to establish the true efficacy of these systems. We are conducting additional studies for more careful comparison among the devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.